Extracellular vesicle-based therapeutics: Extracellular vesicles as therapeutic targets and agents.


Journal

Pharmacology & therapeutics
ISSN: 1879-016X
Titre abrégé: Pharmacol Ther
Pays: England
ID NLM: 7905840

Informations de publication

Date de publication:
02 2023
Historique:
received: 29 11 2022
revised: 06 01 2023
accepted: 19 01 2023
pubmed: 27 1 2023
medline: 3 3 2023
entrez: 26 1 2023
Statut: ppublish

Résumé

Extracellular vesicles (EVs) are cell-derived membrane vesicles composed of a lipid bilayer. EVs contain biological molecules, such as nucleic acids, lipids, and proteins. As these molecules are transferred to cells that receive EVs, EVs function as intercellular communication tools. EV-mediated intercellular communication is involved in various diseases, such as cancer and neurodegenerative diseases, and biological events, such as immune reactions and inflammation. Therefore, EVs are suggested to be useful as therapeutic targets for various diseases. However, an EV-based drug delivery system (DDS) that utilizes its therapeutic properties has not yet been reported. The biological activities of EVs are derived from their endogenous components; hence, they can be directly applied as drugs. In this review, the basic aspects of EVs, such as their types, methods of isolation, and in vivo behavior, are briefly summarized. Moreover, the potential of using therapeutics targeting EVs has been discussed in cancer and neurodegenerative diseases. Various therapeutics using EVs, including DDSs, are listed and their associated advantages and challenges are discussed.

Identifiants

pubmed: 36702209
pii: S0163-7258(23)00016-5
doi: 10.1016/j.pharmthera.2023.108352
pii:
doi:

Substances chimiques

Proteins 0
Nucleic Acids 0

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

108352

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that there are no conflicts of interest.

Auteurs

Yuki Takahashi (Y)

Graduate School of Pharmaceutical Sciences, Kyoto University; 46-29 Yoshida-Shimo-Adachi, Sakyo-ku, Kyoto 606-8501, Japan.

Yoshinobu Takakura (Y)

Graduate School of Pharmaceutical Sciences, Kyoto University; 46-29 Yoshida-Shimo-Adachi, Sakyo-ku, Kyoto 606-8501, Japan. Electronic address: takakura@pharm.kyoto-u.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH